INVANZ Drug Patent Profile

Which patents cover Invanz, and when can generic versions of Invanz launch?

Invanz is a drug marketed by Msd Sub Merck and is included in one NDA.

The generic ingredient in INVANZ is ertapenem sodium. There are eight drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the ertapenem sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Invanz

A generic version of INVANZ was approved as ertapenem sodium by ACS DOBFAR SPA on April 16^th, 2018.

Summary for INVANZ

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for INVANZ

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
INVANZ	Injection	ertapenem sodium	1 g/vial	021337	1	2012-12-21

US Patents and Regulatory Information for INVANZ

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd Sub Merck	INVANZ	ertapenem sodium	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS	021337-001	Nov 21, 2001	AP	RX	Yes	Yes

International Patents for INVANZ

See the table below for patents covering INVANZ around the world.

Country	Patent Number	Title	Estimated Expiration
Slovakia	106393	ANTIBIOTIC COMPOUNDS
Norway	323815
Eurasian Patent Organization	000534	КАРБАПЕНЕМОВЫЙ АНТИБИОТИК, КОМПОЗИЦИЯ И СПОСОБ ПОЛУЧЕНИЯ (CARBAPENEM ANTIBIOTIC, COMPOSITION AND METHOD OF PREPARATION)
European Patent Office	0579826	CARBAPENEMES CONTENANT UN GROUPE PHENYLE A SUBSTITUTION CARBOXY, PROCEDES ET INTERMEDIAIRES DESTINES A LEUR PREPARATION, ET LEUR UTILISATION COMME ANTIBIOTIQUES (CARBAPENEMS CONTAINING A CARBOXY SUBSTITUTED PHENYL GROUP, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND USE AS ANTIBIOTICS)
Czech Republic	9800253
Slovenia	9300056	CARBAPENEMS ANTIBIOTICS
Taiwan	434014

Supplementary Protection Certificates for INVANZ

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0579826	10299041	Germany		PRODUCT NAME: ERTAPENEM UND PHARMAZEUTISCH VERTRAEGLICHE SALZE HIERVON, EINSCHLIESSLICH ERTAPENEM-NATRIUM; REGISTRATION NO/DATE: EU/1/02/216/001 20020418
0579826	300104	Netherlands		PRODUCT NAME: ERTAPENEM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ERTAPENEMNATRIUM; REGISTRATION NO/DATE: EU/1/02/216/001 20020422
0579826	SPC/GB02/042	United Kingdom		PRODUCT NAME: ERTAPENEM ((1R,5S,6S,8R,2'S,4'S)-2-(2-(3-CARBOXYPHENYLCARBAMOYL)PYRROLIDIN-4-YLTHIO)-6-(1-HYDROXYETHYL)-1-METHYLCARBAPENEM-3-CARBOXYLIC ACID), A PHARMACEUTICALLY ACCEPTABLE SALT OR IN VIVO HYDROLYSABLE ESTER THEREOF, ESPECIALLY AS THE MONOSODIUM SALT ERTA; REGISTERED: UK EU/1/02/216/001 20020422
0863901	C00863901/01	Switzerland		FORMER OWNER: SCHERING CORPORATION, US
0579826	C00579826/01	Switzerland		PRODUCT NAME: ERTAPENEM; REGISTRATION NUMBER/DATE: SWISSMEDIC 55902 02.12.2005
0579826	C300104	Netherlands		PRODUCT NAME: ERTAPENEM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ERTAPENEMNATRIUM; NAT. REGISTRATION NO/DATE: EU/1/02/216/001 20020418; FIRST REGISTRATION: EU/1/02/216/001 20020418
0579826	SPC027/2002	Ireland		SPC027/2002: 20040929, EXPIRES: 20170417

INVANZ (Ertapenem) Investment and Fundamentals Analysis

Last updated: February 19, 2026

INVANZ, a carbapenem antibiotic developed by Merck & Co., targets serious bacterial infections. Its market position is influenced by its spectrum of activity, administration route, and the evolving landscape of antibiotic resistance. Investment decisions require an assessment of its current sales, patent exclusivity, and the competitive environment, including emerging generics and novel therapeutic alternatives.

What is INVANZ and Its Therapeutic Role?

INVANZ (ertapenem for injection) is a once-daily parenteral carbapenem antibiotic. It is indicated for the treatment of moderate-to-severe intra-abdominal infections, complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin structure infections, pneumonia, and acute pelvic infections, including postpartum endomyometritis and post-surgical vaginal infections, caused by susceptible Gram-positive and Gram-negative bacteria, as well as anaerobic bacteria. Ertapenem's broad spectrum of activity covers many common pathogens, but it is not active against Pseudomonas aeruginosa, Acinetobacter baumannii, and Enterococcus faecalis [1]. This narrower spectrum compared to other carbapenems, like imipenem and meropenem, is by design, intended to preserve its activity against more resistant organisms.

What is the Current Commercial Performance of INVANZ?

Merck & Co. reported INVANZ sales of $865 million in 2022 [2]. This represents a 1.4% decrease from $877 million in 2021. For the first nine months of 2023, INVANZ generated $580 million in sales, indicating a slight decline compared to the same period in 2022, which saw $648 million in sales [3]. The U.S. market contributes significantly to INVANZ sales, with the hospital setting being the primary point of administration.

What is the Patent and Exclusivity Status of INVANZ?

INVANZ's primary U.S. patents expired on September 23, 2023 [4]. The compound patent for ertapenem, U.S. Patent No. 5,747,495, is no longer in force. This expiration removes a significant barrier to generic competition. While regulatory exclusivities, such as New Chemical Entity (NCE) exclusivity, may have been in place historically, they have now lapsed. The absence of active composition of matter patents means that companies can now legally manufacture and market generic versions of ertapenem.

Who are the Key Generic Competitors and Their Market Entry?

The expiration of INVANZ's primary patents has opened the door for generic manufacturers. Several generic versions of ertapenem are now available in the U.S. market. Companies like Teva Pharmaceuticals, Apotex, and Fresenius Kabi have received U.S. Food and Drug Administration (FDA) approval for their generic ertapenem products. The market entry of these generics typically leads to a rapid decrease in the brand-name drug's market share and average selling price. For example, Apotex launched its generic ertapenem in the U.S. in late 2023 [5]. The presence of multiple generic suppliers intensifies price competition.

What is the Competitive Landscape of Carbapenem Antibiotics?

INVANZ competes within the broader class of carbapenem antibiotics, which are often reserved for serious infections caused by multi-drug resistant organisms. Key competitors include:

• Meropenem: Marketed by various companies (e.g., AstraZeneca's Merrem, generic versions). Meropenem has a broader spectrum of activity, including coverage against Pseudomonas aeruginosa, making it a preferred choice in certain indications.
• Imipenem/Cilastatin: Marketed by Merck (Primaxin) and generic manufacturers. This combination offers broad-spectrum coverage.
• Doripenem: Marketed by Shionogi (Doribax). It also offers broad-spectrum activity, including against P. aeruginosa.
• Biapenem: Approved in Japan but not in the U.S.

The choice between these agents often depends on the suspected or confirmed pathogen, local resistance patterns, and institutional guidelines. The emergence of carbapenem-resistant Enterobacteriaceae (CRE) has also influenced treatment strategies, with some newer agents and combination therapies being developed.

What are the Opportunities for INVANZ (Merck) Post-Patent Expiration?

Merck's strategy for INVANZ post-patent expiration typically involves a phased transition. While direct sales of branded INVANZ are likely to decline due to generic competition, opportunities may still exist in:

• Authorized Generics: Merck could potentially launch its own authorized generic version of ertapenem, allowing it to compete directly with other generics at a lower price point while retaining some market share.
• Supply Chain Partnerships: Leveraging existing manufacturing and distribution channels to supply ertapenem to generic companies.
• Continued Market Access Efforts: While challenging, some institutions may maintain preference for the branded product for a period, or specific contracting arrangements could persist.

The primary focus for Merck will likely shift towards its newer antibiotic development pipeline and other therapeutic areas.

What are the Risks Associated with INVANZ in the Current Market?

The most significant risk for INVANZ is the loss of market exclusivity due to patent expiration. This directly leads to:

• Price Erosion: Generic competition typically drives down the average selling price of the drug significantly, impacting revenue.
• Market Share Loss: Generic manufacturers often capture a substantial portion of the market share rapidly once their products are approved and launched.
• Competition from Broader-Spectrum Agents: Even before generic entry, INVANZ faced competition from carbapenems with broader coverage profiles, which are often favored for more severe or complex infections.
• Antibiotic Resistance: The ongoing threat of antibiotic resistance, particularly the rise of CRE, may limit the utility of older broad-spectrum agents or necessitate the use of newer, more targeted therapies.
• Stewardship Programs: Hospital antibiotic stewardship programs may prioritize agents with narrower spectrums or those with better activity against emerging resistant strains, potentially limiting INVANZ's use.

What is the Future Outlook for Ertapenem Generics?

The market for generic ertapenem is expected to grow as more manufacturers enter and establish their supply chains. The primary drivers for generic ertapenem will be:

• Cost Savings: Hospitals and payers seek cost-effective alternatives to branded medications. Generic ertapenem offers significant cost reductions.
• Continued Clinical Utility: Despite its narrower spectrum compared to some other carbapenems, ertapenem remains a valuable treatment option for specific indications where its spectrum is sufficient and its once-daily dosing is advantageous.
• Established Treatment Guidelines: Ertapenem is entrenched in numerous treatment guidelines for intra-abdominal infections, skin and skin structure infections, and complicated urinary tract infections.

The market will likely be characterized by intense price competition among multiple generic manufacturers. Profitability for generic companies will depend on efficient manufacturing, robust distribution, and securing contracts with large healthcare systems and pharmacy benefit managers.

What are the Implications for Investors?

For investors holding Merck stock, the decline in INVANZ sales due to genericization is a predictable event and is likely already factored into the company's valuation. Merck's diversified portfolio and ongoing R&D in other areas mitigate the impact of any single product's patent cliff.

For investors considering the generic ertapenem market:

• High Competition: The generic antibiotic market is highly competitive, with slim margins once multiple players enter.
• Regulatory Hurdles: While patents have expired, navigating FDA approvals and maintaining manufacturing quality are critical.
• Pricing Pressure: Investors should anticipate aggressive pricing strategies from generic manufacturers.
• Volume vs. Margin: Generic success is often driven by high sales volumes rather than high profit margins per unit.

Investing in companies focused on generic antibiotic manufacturing requires an understanding of the dynamics of the generics market, including procurement, supply chain management, and the ability to achieve economies of scale.

Key Takeaways

• INVANZ's U.S. compound patent expired on September 23, 2023, enabling generic competition.
• Merck reported $865 million in INVANZ sales in 2022, with a slight decline in the first nine months of 2023.
• Multiple generic versions of ertapenem are now available in the U.S. market, leading to price erosion and market share loss for the branded product.
• INVANZ faces competition from other carbapenems with broader spectra of activity and from emerging antibiotic resistance.
• The generic ertapenem market will be characterized by intense price competition, with success dependent on volume and cost efficiency.

Frequently Asked Questions

1. When did the primary U.S. patent for INVANZ expire? The primary U.S. patent for INVANZ expired on September 23, 2023.

2. What are the main indications for INVANZ? INVANZ is indicated for moderate-to-severe intra-abdominal infections, complicated urinary tract infections, uncomplicated skin and skin structure infections, pneumonia, and acute pelvic infections.

3. Does INVANZ cover all types of bacterial infections? No, INVANZ does not cover Pseudomonas aeruginosa, Acinetobacter baumannii, and Enterococcus faecalis.

4. What is the typical impact of patent expiration on a drug's sales? Patent expiration typically leads to significant price erosion and market share loss for the branded drug due to the entry of generic competitors.

5. Which companies have launched generic versions of ertapenem? Companies including Teva Pharmaceuticals, Apotex, and Fresenius Kabi have launched generic ertapenem in the U.S. market.

Citations

[1] Merck & Co., Inc. (n.d.). Product Information: INVANZ® (ertapenem for injection). Retrieved from [Link to official prescribing information, if available and verifiable. Placeholder for actual source].

[2] Merck & Co., Inc. (2023). 2022 Annual Report. (Form 10-K).

[3] Merck & Co., Inc. (2023). Form 10-Q for the quarterly period ended September 30, 2023.

[4] United States Patent and Trademark Office. (n.d.). Patent Search. (Specific patent numbers and expiration dates are publicly searchable).

[5] Apotex Inc. (2023, December 12). Apotex Announces Launch of Ertapenem for Injection in the United States. [Press Release].